AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome
December 10, 2024 07:00 ET
|
AC Immune SA
AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome ACI-24.060 was generally safe and well tolerated in individuals with Down syndrome with no serious...
AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
August 06, 2024 07:00 ET
|
AC Immune SA
AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update Announced exclusive option and license agreement with Takeda for ACI-24.060 on May 13 for $100 million upfront...
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
May 13, 2024 06:00 ET
|
AC Immune SA
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease Takeda to receive exclusive option to license global rights...